IXICO PLC (IXI)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
11.50p
Buy
12.00p
-0.09p (-0.77%)
Prices updated at 16 Dec 2025, 15:12 GMT
| Prices minimum 15 mins delay
Prices in GBX
IXICO PLC is engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Mark Robert Warne
CEO
Mr. Bram Goorden
Most recent earnings
30 Sep 2025
Fiscal year end
30 Sep 2025
Employees
79
Head office
15 Long Lane
London
United Kingdom
EC1A 9PN
Key personnel
Owner name | Salary |
|---|---|
Mr. Mark Robert Warne Non-Executive Director, Chairman | - |
Dr. Dipti Mahendra Amin Non-Executive Director | - |
Ms. Katherine Jane Rogers Non-Executive Director | - |
Mr. Grant Robert Nash Executive Director, Chief Financial Officer, Chief Operating Officer and Company Secretary | - |
Mr. Bram Goorden Executive Director, Chief Executive Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Unicorn Asset Management Ltd | 3,586,000 |
| Unicorn AIM VCT Series 3 ORD | 3,586,000 |
| Octopus Investments Limited | 3,427,027 |
| M & G Investment Management | 100,000 |
| LUX IM Global Medtech | 100,000 |
Director dealings
Date | Action |
|---|---|
| 12 Jun 2025 | Purchase |
| 12 Jun 2025 | Sale |
Please note that past performance is not a reliable indicator of future returns.
